Based on these results, BIRC2 could be a target and useful biomarker for personalised treatment of patients with HNSCC, which might contribute to the development of more effective ways of diagnosing and treating HNSCC, thereby improving patient outcomes. The gene discussed is BIRC2; the disease is head and neck squamous cell carcinoma.